APA

Warren N. J. H., Donahue K. L. & Eastman A. (2019). Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38. : ACS pharmacology & translational science.

Chicago

Warren Nicholas J H, Donahue Katelyn L and Eastman Alan. 2019. Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38. : ACS pharmacology & translational science.

Harvard

Warren N. J. H., Donahue K. L. and Eastman A. (2019). Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38. : ACS pharmacology & translational science.

MLA

Warren Nicholas J H, Donahue Katelyn L and Eastman Alan. Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38. : ACS pharmacology & translational science. 2019.